Published: 24th March 2020

University of Birmingham spinout Linear Diagnostics Ltd is to develop a rapid test for chlamydia and gonorrhoea that can detect infection from a single sample, allowing diagnosis and treatment in a single patient visit.

Globally, more than 1 million STIs are contracted every day.1 The latest UK figures show a 5% increase in diagnoses between 2017 and 2018, due to a large increase in the number of diagnoses for gonorrhoea (26%; from 44,812 to 56,259) and chlamydia (6%; from 205,365 to 218,095).2

Rapid and appropriate antibiotic treatment is essential for both infections; chlamydia is largely asymptomatic and can cause infertility in women, and in gonorrhoea antimicrobial resistance has emerged to all previously used first line drugs – and the first strain resistant to dual therapy with ceftriaxone plus high-level azithromycin was isolated in England and Australia in 2018.3

Dr Matt Hicks, CTO and Founder of Linear Diagnostics Limited, said: “Point of care diagnosis means that sexual health clinics can deliver diagnosis and treatment in a single visit. It is critical to break the chain of person-to-person transmission, particularly as drug resistant strains are on the rise, and people who present for testing may not return to the clinic to collect test results and treatment.”

Linear Diagnostics was founded by researchers from the School of Biosciences at the University of Birmingham, Professor Tim Dafforn and Dr Matt Hicks. The pair aimed to develop diagnostic devices based on patented technologies that use linear dichroism – which uses polarized light to detect the presence of molecules in solution.

The move into sexual health follows £2m funding to further develop the technique to identify key gene sequences in a sample.  The funders expect that the company’s technology will be able to detect multiple genetic targets from a single sample within a 15 minute timescale.  Full details of the investment package can be found here.

ENDS

For further media information contact:  Ruth Ashton, Reputation & Communications Development Manager, r.c.ashton@bham.ac.uk, tel: 0121 414 9090, mob: 07989 558041.

Notes to editors:

  • The June 2019 WHO Bulletin (published online) reported over 127 million new cases of chlamydia in 2016, and 87 million of gonorrhoea1
  • In the same month, Public Health England reported a total of 447,694 diagnoses of STIs in 2018.  This represents an increase of 5% from from 2017 (424,724 diagnoses), due to a large increase in gonorrhoea and a more moderate increase in chlamydia infections
    • Although the largest proportional increase in gonorrhoea and chlamydia were in people 65 years and above (gonorrhoea – 42%; chlamydia – 24%), the highest infection rates are amongst the 15-24 year age group.2

About Linear Diagnostics Limited

Founded in 2011, Linear Diagnostics Limited exploits the phenomenon of linear dichroism (LD) for a number of uses, ranging from detection of antibiotic resistant infections, to testing for bacteria that cause rotting in food crops. LDL explores a novel platform technology that can be used for assays in a wide range of sectors.

About University of Birmingham Enterprise

University of Birmingham Enterprise supports academics who want to innovate, take their ideas to market, work with businesses and social enterprises, or enrich their professional lives by doing academic consultancy projects.  We do this by providing enterprise training, funding, office and laboratory space, and a full technology transfer service.   University of Birmingham Enterprise also manages the incubation services and facilities at the Birmingham Research Park.

About the University of Birmingham

The University of Birmingham is ranked amongst the world’s top 100 institutions. Its work brings people from across the world to Birmingham, including researchers, teachers and more than 5,000 international students from over 150 countries.

References

  1. Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, Bulletin of the World Health Organization, doi: http://dx.doi.org/10.2471/BLT.18.228486
    1. Sexually transmitted infections and screening for chlamydia in England, Public Health England, 2018 Health Protection Report, Volume 13 Number 19, published 7 June 2019
    2. World Health Organization Global Gonococcal Antimicrobial Surveillance Program (WHO GASP): review of new data and evidence to inform international collaborative actions and research efforts, Sexual Health, doi: https://doi.org/10.1071/SH19023

Published:

Birmingham-based Linear Diagnostics Limited has secured £2m of investment from MEIF and other investors to develop new platform technology for medical diagnostic testing.

Following extensive research, the spin-out from the University of Birmingham is to create a platform that is able to provide multiple diagnoses in a Point of Care environment.

The funding round was led by venture capital firm Midven, using equity finance from the Midlands Engine Investment Fund (MEIF).

The round also included investment from the UK Innovation Science and Seed Fund, the University of Birmingham, Abingdon Health and the company’s directors.

Linear Diagnostics’ platform uses the disruption of polarised light to measure changes in DNA sequences, offering a rapid and low cost method to identify key gene sequences.

The firm’s first test of the platform will see it target sexually transmitted diseases. The ability to detect drug resistant infections and rapidly identify the causal agent allows screening and treatment during a single patient visit.

The World Health Organisation has recognised this is not yet capable of being achieved using alternative diagnostic approaches – Linear Diagnostics’ platform will eventually be able to diagnose multiple genetic targets from a single sample within a 15 minute timescale.

LDL was formed in 2011 by its founders Professor Tim Dafforn and Dr Matt Hicks, based on their patented research in the field of Linear Diachroism – using polarised light to identify changes at a molecular level.

Linear

(l-r) Junior Research Scientist Jake Cotterill, Research Scientist Lorea Orueta, Linear Diagnostics Ltd Chief Technology Officer Mathew Hicks, UK Innovation & Science Seed Fund Manager Oliver Sexton, Linear Diagnostics Ltd Chairman and CEO Brendon Farrell, Linear Diagnostics Ltd Non-Executive Director David Wilson, Midven Director Roger Wood, Senior Research Scientist Jean-Louis Duprey and British Business Bank Senior Funds Operation Manager Dave Tindall

“We’re at a really exciting stage of our development and this round of investment is a fantastic opportunity for us take our explorations and anaylsis to the next level,” said Matt Hicks, CTO and founder of Linear Diagnostics Limited.

“The funding will help us accelerate time to market of our initial product, through further investment in technical resource and beginning hardware development.”

Roger Wood, director at Midven, said: “Linear Diagnostics is an early stage business with huge potential, and is at an important and exciting juncture of its product development.

“It’s targeting a fast growing segment of the diagnostics market, and we are delighted to have led this significant funding round; this will enable the company to deliver on the next stage of its plans.”

Oliver Sexton, investment director of the UK Innovation Science and Seed Fund, said: “UKI2S backed the company to develop its molecular diagnostic capability. The platform’s rapid readout is unique, allowing diagnoses based on the presence or absence of key gene sequences with unparalleled accuracy.”

The MEIF project is supported financially by the European Union using funding from the European Regional Development Fund (ERDF) as part of the European Structural and Investment Funds Growth Programme 2014-2020 and the European Investment Bank.

Published: 3rd March 2020

University of Birmingham spinout Linear Diagnostics Ltd has raised £2m to develop a rapid test for chlamydia and gonorrhoea which can detect infection from a single sample, allowing diagnosis and treatment in a single patient visit.

Globally, more than 1 million STIs are contracted every day.1 The latest UK figures show a 5% increase in diagnoses between 2017 and 2018, due to a large increase in the number of diagnoses for gonorrhoea (26%; from 44,812 to 56,259) and chlamydia (6%; from 205,365 to 218,095).2

Rapid and appropriate antibiotic treatment is essential for both infections; chlamydia is largely asymptomatic and can cause infertility in women, and in gonorrhoea antimicrobial resistance has emerged to all previously used first line drugs – and the first strain resistant to dual therapy with ceftriaxone plus high-level azithromycin was isolated in England and Australia in 2018.3

Dr Matt Hicks, CTO and Founder of Linear Diagnostics Limited, said: “Point of care diagnosis means that sexual health clinics can deliver diagnosis and treatment in a single visit. It is critical to break the chain of person-to-person transmission, particularly as drug resistant strains are on the rise, and people who present for testing may not return to the clinic to collect test results and treatment.”

Linear Diagnostics was founded by researchers from the School of Biosciences at the University of Birmingham, Professor Tim Dafforn and Dr Matt Hicks. The pair aimed to develop diagnostic devices based on patented technologies that use linear dichroism – which uses polarized light to detect the presence of molecules in solution.

This latest funding round of £2m is to further develop the technique to identify key gene sequences in a sample, and the funders expect that the company’s technology will be able to detect multiple genetic targets from a single sample within a 15 minute timescale.

Midven saw a significant opportunity in Linear Diagnostics’ technology, which is being developed for point of care STI testing.

Roger Wood, Director at Midven, explained: “Linear Diagnostics is at an important and exciting juncture of its product development. It’s targeting a fast growing segment of the diagnostics market with a technology that can deliver a range of tests for multiple targets, and this provides more value as a proposition than single tests for pathogens.”

Under the chairmanship of Brendan Farrell, a diagnostics industry veteran with over 30 years experience in high-growth companies, Linear has grown to seven staff and is now looking for collaborations for the development of single-use cartridges and a portable reader device.

The funding round was led by Birmingham venture capital firm Midven, using equity finance from the Midlands Engine Investment Fund (MEIF), and included investment from the UK Innovation Science and Seed Fund (UKi2S), the University of Birmingham, and Linear Diagnostics’ directors. The full funding package of £2m also includes grant money and convertible loans.

Oliver Sexton, Investment Director at UKi2S, commented: “Linear’s technology rapidly identifies key gene sequences in samples. This is critical in an era when antibiotic resistance is on the rise, as it enables medical staff to choose the appropriate antibiotic at the earliest possible opportunity. As an early investor in the technology, we are looking forward to it’s next stage of development.”

The MEIF project is supported financially by the European Union using funding from the European Regional Development Fund (ERDF) as part of the European Structural and Investment Funds Growth Programme 2014-2020 and the European Investment Bank.

Full details of the investment package can be viewed here.